Novartis Showcases Major North Carolina Expansion, Building A Flagship U.S. Manufacturing Hub

Novartis has announced a major expansion of its U.S. manufacturing presence with plans to establish a large, integrated flagship hub in North Carolina. The new investment is part of the company’s broader $23 billion U.S. infrastructure commitment over five years, aimed at ensuring that all key Novartis medicines for U.S. patients are produced domestically. The hub will support end-to-end manufacturing, enabling medicines to be produced, packaged, and distributed entirely within the United States.

“This announcement is a commitment to American innovation and to the patients we serve,” said Vas Narasimhan, CEO of Novartis. “By building a full, end-to-end manufacturing presence in North Carolina for our broader portfolio, we are expanding our capacity to deliver medical breakthroughs, securing a more resilient US supply chain, and investing in the local communities that make our mission possible.” 

The expansion includes construction of two new biologics and sterile packaging facilities in Durham, a new solid oral dosage manufacturing site in Morrisville, and enhancements to the current Durham facility, which will add sterile filling capabilities. These sites will connect with Novartis’ broader U.S. production network for cell and gene therapies, radioligand therapies, and future xRNA medicines. By consolidating operations, Novartis aims to streamline manufacturing for treatments across oncology, immunology, neuroscience, and cardiovascular and metabolic diseases.

“North Carolina continues to lead in advanced pharmaceutical manufacturing, and Novartis’ expansion in the Triangle reflects our state’s talent and innovative spirit,” said Governor Josh Stein. “This investment will strengthen our state’s economy and ensure life-saving medicines continue to be made right in North Carolina.”

Scheduled to open between 2027 and 2028, the North Carolina hub will span more than 700,000 square feet and is projected to create 700 direct jobs at Novartis and over 3,000 indirect jobs by 2030. The move strengthens North Carolina’s already growing pharmaceutical manufacturing ecosystem, supports local workforce development, and reinforces the company’s long-term strategy to scale domestic production of advanced medicines.